Research never stops

Top Story

Evotec and Bayer advance endometriosis programme into Phase I clinical development and extend alliance

Hamburg, Germany, 24 July 2017: Evotec AG announced today that its multi-target endometriosis alliance with Bayer has advanced a programme from the alliance portfolio into Phase I clinical development for the treatment of endometriosis, triggering a milestone payment to Evotec.

- read more

Evotec received funding from IFB Hamburg to identify antibody-mediated t-cell immunotherapies

Hamburg, Germany, 06 July 2017:
Evotec AG announced today that the Company has been awarded a 'Programm für Innovation' grant for a period of two years from the  Hamburgische Investitions- und Förderbank, the central development institution of the Free and Hanseatic city of Hamburg, to identify and develop therapeutic antibodies directed against novel immune-checkpoints on T-cells to improve future cancer treatments.

- read more

Evotec expands iPSC drug discovery leadership through strategic collaboration with Censo Biotechnologies

Hamburg, Germany, 28 June 2017: Evotec AG today announced a collaboration with Censo Biotechnologies Ltd. to source and provide patient-derived induced pluripotent stem cells to support Evotec's broad iPSC platform.

- read more
loading weather report
Loading weather report...


Sep 08, 2017 - 7th Annual Biotech Symposium

Company Presentation July

Building integrated and high-value drug discovery alliances
2017-07_Evotec_Company presentation_July